Pierre Danneels

Pierre Danneels

Auto-generated profile, based on publicly available information

Pierre Danneels

Department of Infectious Diseases and Tropical Medicine, Angers University Hospital , Angers

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Journal of Infection
Verified
Journal Article
Closed access
PDPierre Danneels
Pierre Danneels
Floris ChabrunFloris Chabrun
Floris Chabrun
LPLéa Picard
Léa Picard
PMPauline Martinet
Pauline Martinet
SRSchéhérazade Rezig
Schéhérazade Rezig
VDVincent Dubee
Vincent Dubee

10 November 2018 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ASAlessio Strazzulla
Alessio Strazzulla
CCCatherine Chakvetadze
Catherine Chakvetadze
MPMarie Picque
Marie Picque
BCBruno Cassard
Bruno Cassard
FHFabien Hernandez
Fabien Hernandez
SDSylvain Diamantis
Sylvain Diamantis

10 September 2020 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
PDPierre Danneels
Pierre Danneels
MPMaria Concetta Postorino
Maria Concetta Postorino
ASAlessio Strazzulla
Alessio Strazzulla
NBNabil Belfeki
Nabil Belfeki
APAurelia Pitch
Aurelia Pitch
SDSylvain Diamantis
Sylvain Diamantis
Introduction. Treatment of Haemophilus influenzae (Hi) pneumonia is on concern because resistance to amoxicillin is largely diffused. This study describes the evolution of resistance to amoxicillin and amoxicillin/clavulanic acid (AMC) in Hi isolates and characteristics of patients with Hi severe pneumonia. Methods. A monocentric retrospective observational study including patients from 2008 to 2017 with severe pneumonia hospitalized in ICU. Evolution of amoxicillin and AMC susceptibility was showed. Characteristics of patients with Hi pneumonia were compared to characteristics of patients with Streptococcus pneumoniae (Sp) pneumonia, as reference. Risk factors for amoxicillin resistance in Hi were investigated. Results. Overall, 113 patients with Hi and 132 with Sp pneumonia were included. The percentages of AMC resistance among Hi strains decreased over the years (from 10% in 2008-2009 to 0% in 2016-2017) while resistance to amoxicillin remained stable at 20%. Also, percentages of Sp resistant strains for amoxicillin decreased over years (from 25% to 3%). Patients with Hi pneumonia experienced higher prevalence of bronchitis (18% vs. 8%, p=0.02, chronic obstructive pulmonary disease (43% vs. 30% p=0.03), HAP (18% vs. 7%, p=0.01, ventilator-associated pneumonia (27% vs. 17%, p=0.04, and longer duration of mechanical ventilation (8 days vs. 6 days, p=0.04) than patients with Sp pneumonia. Patients with Sp pneumonia had more frequently local complications than patients with Hi pneumonia (17% vs. 7%, p=0.03). De-escalation of antibiotics was more frequent in patients with Sp than in patients with Hi (67% vs. 53%, p=0.03). No risk factors were associated with amoxicillin resistance among patients with Hi pneumonia. Conclusions. Amoxicillin resistance was stable over time, but no risk factors were detected. AMC resistance was extremely low, suggesting that AMC could be used for empiric treatment of Hi pneumonia, as well as other molecules, namely, cephalosporins. Patients with Hi pneumonia had more pulmonary comorbidities and severe diseases than patients with Sp pneumonia.

14 May 2024 in Infectious Diseases Now
Verified
Journal Article
Closed access
PMPauline Martinet
Pauline Martinet
LLLuca Lanfranco
Luca Lanfranco
ACAnne Coste
Anne Coste
DTDidier Tandé
Didier Tandé
PDPierre Danneels
Pierre Danneels
SRSchéhérazade Rezig
Schéhérazade Rezig

12 December 2025 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
PDPierre Danneels
Pierre Danneels
FCFloris Chabrun
Floris Chabrun
LGLucia Grandière-Pérez
Lucia Grandière-Pérez
ATAli Touré
Ali Touré
VDVincent Dubee
Vincent Dubee
NOVA and DENOVA scores were developed to guide endocarditis risk assessment in Enterococcus faecalis Bacteremia (EfB), but some of their criteria may be open to interpretation. We aimed to evaluate their inter-rater reliability and feasibility. Thirty-two physicians from four specialties involved in the management of endocarditis independently evaluated eight EfB patient records using the NOVA and DENOVA scores. Each score was applied eight times per case. Inter-rater reliability was measured with Krippendorff's alpha, and agreement with Fleiss' Kappa. Completion time was also recorded. No record received identical scores from all raters. NOVA showed low inter-rater reliability (α = 0.37), while DENOVA reached moderate levels (α = 0.49). High agreement was found for extreme score values, but agreement dropped markedly for intermediate values. Among score items, Auscultation of murmur (A) and Valve disease (V) had the highest reliability (α > 0.8), while Duration of symptoms (D) and Origin of infection (O) had the lowest (α < 0.2). Completion times were similar between NOVA and DENOVA but varied by specialty. The reproducibility of these scores is limited, especially near critical thresholds, highlighting the need to complement scoring tools with clinical judgment in EfB.

7 April 2026 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDPierre Danneels
Pierre Danneels
FCFloris Chabrun
Floris Chabrun
BCBaptiste Clément
Baptiste Clément
XDXavier Duval
Xavier Duval
VDVincent Dubée
Vincent Dubée